CARLSBAD, Calif., June 11, 2026
Arima Genomics, a cancer diagnostics company focused on integrating DNA sequence and genome structure analysis, announced new data demonstrating that its Hi-C sequencing technology significantly outperformed high-coverage whole genome sequencing (WGS) in detecting clinically relevant lymphoma rearrangements. The findings will be presented at the Association for Molecular Pathology (AMP) Europe 2026 Congress in Tallinn, Estonia, and further strengthen the clinical value of the company’s Aventa Lymphoma test for identifying important genomic alterations that influence lymphoma diagnosis, prognosis, and treatment selection.
Hi-C Sequencing Detects Critical Lymphoma Rearrangements Missed by Whole Genome Sequencing
The study evaluated 25 FFPE lymphoma tissue specimens containing 37 clinically relevant structural variants that had previously been identified through Hi-C sequencing and validated using orthogonal testing methods. Researchers compared these results against high-coverage WGS data generated at an average sequencing depth of 180× coverage. Despite the extensive sequencing depth, both leading WGS analysis pipelines failed to detect a substantial proportion of clinically important rearrangements. The DRAGEN Somatic Pipeline identified only 19 of 37 rearrangements (51% recall), while Sentieon TNscope achieved somewhat higher detection rates but still missed several significant alterations. The missed rearrangements included abnormalities involving critical lymphoma-associated genes such as MYC, BCL2, BCL6, CCND1, and IRF4, all of which play important roles in lymphoma classification and treatment decision-making.
Superior Performance Over Conventional Genomic Testing Approaches
The analysis revealed particularly poor performance of WGS in detecting immunoglobulin-associated rearrangements, which are among the most clinically relevant genomic events in lymphoma. DRAGEN detected only 44% of immunoglobulin-associated rearrangements, while Sentieon identified 50%, highlighting the limitations of conventional sequencing approaches in capturing complex structural genomic events. Arima stated that Hi-C sequencing directly analyzes three-dimensional genome architecture, providing a more comprehensive view of structural rearrangements than standard sequencing methods.
Advertisement
The findings build upon previously reported studies showing that Hi-C sequencing can overcome limitations of fluorescence in situ hybridization (FISH) by enabling genome-wide detection of diagnostic, prognostic, and therapeutic biomarkers from routine FFPE lymphoma samples. According to the company, this capability may help clinicians identify clinically actionable alterations that could otherwise remain undetected using traditional diagnostic methods.
Expanding the Future of Precision Diagnostics in Lymphoma
Arima Genomics believes the new data support the growing role of Hi-C sequencing as a next-generation genomic diagnostic platform for hematologic malignancies. Company scientists emphasized that structural rearrangements remain central to lymphoma diagnosis and disease classification, yet many existing technologies were not specifically designed to capture genome architecture. By combining DNA sequence information with structural genome analysis, Hi-C sequencing may provide a more complete genomic profile capable of improving diagnostic accuracy and supporting precision medicine strategies.
Additional data presented at AMP Europe 2026 will further compare Hi-C sequencing with FISH and evaluate its ability to identify guideline-recommended and emerging lymphoma biomarkers. The company expects these findings to strengthen the clinical utility of its Aventa testing platform and accelerate broader adoption of genome-structure-based diagnostics in oncology.
Advancing Comprehensive Cancer Genomics Through Hi-C Technology
As precision oncology increasingly depends on comprehensive genomic characterization, technologies capable of identifying complex structural alterations are becoming more important. Arima Genomics is positioning its Hi-C sequencing platform as a solution capable of detecting clinically significant rearrangements that may be missed by conventional testing approaches. The company’s research highlights the growing importance of genome architecture analysis in cancer diagnostics and suggests that integrating structural genomic information could improve patient stratification, treatment selection, and disease monitoring across lymphoma and other cancer types.
Source: Arima Genomics, press release
